Investor profile
Roche Venture Fund has backed 8 European tech companies across 10 funding rounds between 2013 and 2025, joining rounds totalling €422M. Most active in Healthtech. Data as of 6 Aug 2026.
Also recorded as: Roche Ventures
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| GlycoEra | Switzerland | 2 | €157M |
| SpliceBio | Spain | 1 | €118M |
| Vivet Therapeutics | France | 1 | €38M |
| NMD Pharma | Denmark | 1 | €35M |
| MISSION Therapeutics | UK |
| 2 |
| €35M |
| DiogenX | France | 1 | €28M |
| Horizon Discovery | UK | 1 | €8.1M |
| MySugr | Austria | 1 | €4.3M |
| Series A |
| €38M |
| 2017-05 |
| NMD Pharma | Other | €35M | 2022-02 |
| DiogenX | Series A | €28M | 2023-05 |
| MISSION Therapeutics | Series B | €24M | 2013-11 |
| MISSION Therapeutics | Other | €11M | 2025-10 |
| Horizon Discovery | Series C | €8.1M | 2013-06 |
| MySugr | Series A | €4.3M | 2015-03 |
